Making Motion: Craft Brew Alliance (NASDAQ:BREW), AAC Holdings (NYSE:AAC), Five Prime Therapeutics (NASDAQ:FPRX), Celator Pharmaceuticals (NASDAQ:CPXX)

Unilever PLC (NYSE:UL) shares decreased -0.85% in last trading session and ended the day at $44.58. UL has a return on assets of 19.90%. Unilever PLC (NYSE:UL) quarterly performance is 4.89%.

RBC Capital reiterated their outperform rating on shares of Unilever plc (NYSE:UL) in a research report sent to investors on Friday. They currently have a GBX 3,200 ($45.79) target price on the stock.

Craft Brew Alliance, Inc. (NASDAQ:BREW) ended the last trading day at $8.57. Company weekly volatility is calculated as 3.16% and price to cash ratio as 182.64. Craft Brew Alliance, Inc. (NASDAQ:BREW) showed a weekly performance of 3.25%.

Craft Brew Alliance, Inc. (NASDAQ:BREW), announced that Paul D. Davis has been appointed to the company’s Board of Directors, effective March 8, 2016. A seasoned business leader with more than three decades of consumer packaged goods experience, Mr. Davis, 58, was most recently Chief Executive Officer of popchips® until August 2015 and became Co-Chairman of its Board of Directors in September 2015.

On 21 March, AAC Holdings, Inc. (NYSE:AAC) shares increased 1.86% and was closed at $20.25. AAC Holdings, Inc. (NYSE:AAC) year to date (YTD) performance is 6.24%.

AAC Holdings, Inc. (NYSE: AAC) announced that after considering the Company’s motions to dismiss the California case, the prosecution’s opposition and related oral arguments by both sides, the Honorable Elaine M. Kiefer granted the defense motion to set aside and dismiss the second degree murder count as to all defendants. The dependent adult abuse charge remains in effect as to all defendants with the exception of Tami Scarcella who was dismissed. The next hearing date is scheduled for April 1, 2016.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shares increased 5.64% in last trading session and ended the day at $37.06. FPRX has a return on assets of 84.40%. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) quarterly performance is -15.29%.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, present at the Barclays Global Healthcare Conference on Thursday, March 17, 2016 at 10:45 AM Eastern Daylight Time.

Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) caters to the Healthcare space. Its weekly performance is 477.98%. On the last day of trading company shares ended up at $9.71.

On 14 March, Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) announced positive results from the Phase 3 trial of VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. Data will be submitted for presentation at the American Society of Clinical Oncology 2016 Annual Meeting.